Elsevier

Neuroscience Letters

Volume 40, Issue 3, 10 October 1983, Pages 245-250
Neuroscience Letters

Increased [3H]kainic acid binding in the prefrontal cortex in schizophrenia

https://doi.org/10.1016/0304-3940(83)90046-0Get rights and content

Abstract

[3H]Kainic acid binding sites were measured post mortem in the putamenand prefrontal cortex areas from 10 control subjects and 12 schizophrenic patients. A 25–50% increase in [3H]kainic acid binding was observed in the medial frontal (Brodmann areas 9, 10 and 46) and eye-movement areas (8), but not in the other regions of schizophrenic brains. No significant correlation between the binding and either age at death, storage of the brains, duration of illness or neuroleptics-free period was observed. These findings suggest that a dysfunction of cortical excitatory amino acidergic transmission may be involved in schizophrenia.

References (16)

There are more references available in the full text version of this article.

Cited by (144)

  • Potential targeting sites in brain and brain tumors

    2022, Nanocarriers for Drug-Targeting Brain Tumors
  • A comparative analysis of kainate receptor GluK2 and GluK5 knockout mice in a pure genetic background

    2021, Behavioural Brain Research
    Citation Excerpt :

    KARs have been linked to psychiatric disorders such as schizophrenia, bipolar disorder, major depressive disorder, and autism [2,8]. In an early pharmacological study, [3H]kainic acid binding sites were measured in the post-mortem brains of schizophrenia patients, and a 25–50 % increase in [3H]kainic acid binding was observed in the medial frontal regions and the areas responsible for eye-movement [9]. The expression of mRNA in KAR subunits is also reduced in the orbitofrontal cortex of patients with schizophrenia [10–12].

  • Positive allosteric modulators of metabotropic glutamate 2 receptors in schizophrenia treatment

    2015, Trends in Neurosciences
    Citation Excerpt :

    Recent findings suggest that the mGlu2Rs are also expressed postsynaptically, where they play a key role in the control of the responses induced by atypical antipsychotics [28–31]. Additional evidence for involvement of glutamate in the pathophysiology of schizophrenia comes from postmortem studies which revealed altered ionotropic glutamate receptor binding and gene expression mainly in the prefrontal cortex and the hippocampus [32–35]. Furthermore, functional neuroimaging studies have shown reduced NMDA binding in the hippocampus of medication-free schizophrenic patients compared to healthy controls [36].

  • Clozapine and GABA transmission in schizophrenia disease models: Establishing principles to guide treatments

    2015, Pharmacology and Therapeutics
    Citation Excerpt :

    A reduction in PFC glutamate transmission is also posited to contribute at least in part to cortical hypofrontality as evidenced by post-mortem reports of decreased PFC glutamate levels in schizophrenia (Tsai et al., 1995). In this regard, an increase in PFC glutamate receptor density as evidenced by increased 3H-kainate binding (Nishikawa et al., 1983) and NMDAR 2D subunit mRNA expression (Akbarian et al., 1996) have been reported in schizophrenia. In addition, a 23% reduction in dlPFC pyramidal neuron dendritic spine number has also been reported in schizophrenia which is suggested to reflect reduced thalamocortical and/or corticocortical afferent input (Glantz & Lewis, 2000).

View all citing articles on Scopus

Supported by Grant 81-13-07 (1981) from National Center for Nervous, Mental and Muscular Disorders of the Ministry of Health and Welfare, Japan.

We thank Drs. T. Kanaya, M. Naito, H. Yamazumi, T. Koizumi, H. Nomura, T. Fujimori, O. Matsuda, S. Ando, S. Takahashi, H. Shimada, H. Morioka, T. Numakura and J. Semba for their help in obtaining specimens. We also thank Drs. K. Kishi, T. Maeda, A. Sakuma, B. Scatton and S. Watanabe for their helpful advice. We are grateful tto Dr. T. Inose for his histopathological examination of the brain of case S3.

View full text